- NCIt
- C223955
Loading cancer entity…
Loading cancer entity…
Clinical trials
59 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (12)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05156268 | A Study of Pembrolizumab and Olaparib in People With Endometrial Cancer or Endometrial Carcinosarcoma | completed | Phase 2 | 26 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Apr 27, 2026 | clinicaltrials |
| NCT03694262 | The EndoBARR Trial (Endometrial Bevacizumab, Atezolizumab, Rucaparib)(EndoBARR) | completed | Phase 2 | 30 | Medical College of WisconsinOTHER | 1 | Apr 13, 2026 |
| NCT05494580 | Pamiparib Plus Surufatinib in Patients With Platinum-resistant Ovarian Cancer | completed | Phase 1 / Phase 2 | 29 | Sun Yat-sen UniversityOTHER | 1 | Mar 10, 2026 | clinicaltrials |
| NCT01935934 | Cabozantinib S-Malate in Treating Patients With Recurrent or Metastatic Endometrial Cancer | completed | Phase 2 | 102 | National Cancer Institute (NCI)NIH | 2 | Oct 1, 2025 | clinicaltrials |
| NCT03552471 | Mirvetuximab Soravtansine and Rucaparib Camsylate in Treating Participants With Recurrent Endometrial, Ovarian, Fallopian Tube or Primary Peritoneal Cancer | completed | Phase 1 | 25 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Feb 13, 2025 | clinicaltrials |
| NCT03648489 | Dual mTorc Inhibition in advanCed/Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer (of Clear Cell, Endometrioid and High Grade Serous Type, and Carcinosarcoma)(DICE) | completed | Phase 2 | 134 | Imperial College LondonOTHER | 2 | Sep 20, 2024 | clinicaltrials |
| NCT03206177 | Paclitaxel/Carboplatin + Galunisertib for Patients With Carcinosarcoma of the Uterus or Ovary | completed | Phase 1 | 26 | University of OklahomaOTHER | 1 | Aug 7, 2024 | clinicaltrials |
| NCT02020707 | Nab-Paclitaxel and Bevacizumab in Treating Patients With Unresectable Stage IV Melanoma or Gynecological Cancers | completed | Phase 1 | 43 | Mayo ClinicOTHER | 1 | Jul 26, 2024 | clinicaltrials |
| NCT03015129 | A Study of Durvalumab With or Without Tremelimumab in Endometrial Cancer | completed | Phase 2 | 80 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Feb 6, 2024 | clinicaltrials |
| NCT00989651 | Carboplatin, Paclitaxel, Bevacizumab, and Veliparib in Treating Patients With Newly Diagnosed Stage II-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer | completed | Phase 1 | 431 | National Cancer Institute (NCI)NIH | 1 | Oct 20, 2021 | clinicaltrials |
| NCT02993705 | Trial On Trabectedin In The Treatment Of Advanced Uterine And Ovarian Carcinosarcoma (CS)(MITO 26) | completed | Phase 2 | 45 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | Aug 25, 2021 | clinicaltrials |
| NCT00478426 | Sunitinib Malate in Treating Patients With Recurrent or Metastatic Endometrial Cancer | completed | Phase 2 | 34 | National Cancer Institute (NCI)NIH | 2 | Feb 17, 2020 | clinicaltrials |
| NCT01168232 | Ixabepilone in Treating Patients With Recurrent or Persistent Uterine Cancer | completed | Phase 2 | 42 | National Cancer Institute (NCI)NIH | 1 | Aug 8, 2019 | clinicaltrials |
| NCT01247571 | Pazopanib Hydrochloride in Treating Patients With Recurrent or Persistent Uterine Cancer | completed | Phase 2 | 22 | National Cancer Institute (NCI)NIH | 1 | Aug 8, 2019 | clinicaltrials |
| NCT00025506 | Thalidomide in Treating Patients With Recurrent or Persistent Carcinosarcoma of the Uterus | completed | Phase 2 | 55 | National Cancer Institute (NCI)NIH | 1 | Jul 24, 2019 | clinicaltrials |
| NCT00075400 | Imatinib Mesylate in Treating Patients With Recurrent or Persistent Uterine Cancer | completed | Phase 2 | 26 | National Cancer Institute (NCI)NIH | 1 | Jul 24, 2019 | clinicaltrials |
| NCT01010126 | Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer | completed | Phase 2 | 252 | National Cancer Institute (NCI)NIH | 2 | Jan 25, 2019 | clinicaltrials |
| NCT00114218 | Gemcitabine and Docetaxel in Treating Patients With Recurrent or Persistent Uterine Cancer | completed | Phase 2 | 28 | Gynecologic Oncology GroupNETWORK | 1 | Jan 8, 2019 | clinicaltrials |
| NCT00659360 | AZD0530 in Treating Patients With Recurrent Locally Advanced or Metastatic Soft Tissue Sarcoma | completed | Phase 2 | 17 | National Cancer Institute (NCI)NIH | 2 | Jun 29, 2018 | clinicaltrials |
| NCT01080521 | Changes in Brain Function in Patients With Stage I, Stage II, Stage III, or Stage IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Who Are Receiving Chemotherapy | completed | — | 247 | Gynecologic Oncology GroupNETWORK | 1 | Apr 12, 2018 | clinicaltrials |
| NCT00511992 | Study of Bevacizumab Followed by Bevacizumab Consolidation for Ovarian Cancer | completed | Phase 2 | 20 | University of OklahomaOTHER | 1 | Jul 2, 2017 | clinicaltrials |
| NCT00390234 | Ziv-aflibercept in Treating Patients With Locally Advanced, Unresectable, or Metastatic Gynecologic Soft Tissue Sarcoma | completed | Phase 2 | 63 | National Cancer Institute (NCI)NIH | 2 | Dec 7, 2015 | clinicaltrials |
| NCT00238121 | Sorafenib in Treating Patients With Advanced or Recurrent Uterine Cancer | completed | Phase 2 | 56 | National Cancer Institute (NCI)NIH | 2 | Nov 20, 2015 | clinicaltrials |
| NCT00352300 | Carboplatin, Paclitaxel, and Pegfilgrastim in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Fallopian Tube, Primary Peritoneal, or Carcinosarcoma Cancer | completed | Phase 1 | 43 | Gynecologic Oncology GroupNETWORK | 1 | Dec 31, 2014 | clinicaltrials |
| NCT00245102 | Sorafenib in Treating Patients With Metastatic, Locally Advanced, or Recurrent Sarcoma | completed | Phase 2 | 147 | National Cancer Institute (NCI)NIH | 1 | May 23, 2014 | clinicaltrials |
Data updated 22 days agoSource updated Apr 27, 2026source: clinicaltrials